Acute Myeloid Leukemia

被引：139

作者：

Rubnitz, Jeffrey E. ^{[1
]}

Gibson, Brenda ^{[2
]}

Smith, Franklin O. ^{[3
]}

机构：

[1] St Jude Childrens Res Hosp, Dept Oncol, Memphis, TN 38105 USA

[2] Royal Hosp Sick Children, Dept Paediat Haematol, Glasgow G3 8SJ, Lanark, Scotland

[3] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp, Med Ctr,Div Hematol Oncol, Cincinnati, OH 45221 USA

来源：

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2010年 / 24卷 / 01期

关键词：

Myeloid; Leukemia; Childhood; MINIMAL RESIDUAL DISEASE; INTERNAL TANDEM DUPLICATION; BONE-MARROW-TRANSPLANTATION; ACUTE-MYELOGENOUS-LEUKEMIA; CHILDRENS-CANCER-GROUP; ACUTE PROMYELOCYTIC LEUKEMIA; PEDIATRIC-ONCOLOGY-GROUP; HIGH-DOSE CYTARABINE; AMEGAKARYOCYTIC THROMBOCYTOPENIC PURPURA; ACUTE MEGAKARYOBLASTIC LEUKEMIA;

D O I：

10.1016/j.hoc.2009.11.008

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Acute myeloid leukemia (AML) is a heterogeneous group of leukemias that result from clonal transformation of hematopoietic precursors through the acquisition of chromosomal rearrangements and multiple gene mutations. As a result of highly collaborative clinical research by pediatric cooperative cancer groups worldwide, disease-free survival has improved significantly during the past 3 decades. Further improvements in outcomes of children who have AML probably will reflect continued progress in understanding the biology of AML and the concomitant development of new molecularly targeted agents for use in combination with conventional chemotherapy drugs.

引用

页码：35 / +

页数：30

共 50 条

[41] Pediatric Acute Myeloid Leukemia Biology and Therapeutic Implications of Genomic Variants [J].

Tarlock, Katherine ;

Meshinchi, Soheil .

PEDIATRIC CLINICS OF NORTH AMERICA, 2015, 62 (01) :75-+

[42] Management of primary refractory acute myeloid leukemia in the era of targeted therapies [J].

McMahon, Christine M. ;

Perl, Alexander E. .

LEUKEMIA & LYMPHOMA, 2019, 60 (03) :583-597

[43] Molecular characterization and testing in acute myeloid leukemia [J].

Wertheim, Gerald B. W. .

JOURNAL OF HEMATOPATHOLOGY, 2015, 8 (03) :177-189

[44] Current and Emerging Therapies for Acute Myeloid Leukemia [J].

Robak, Tadeusz ;

Wierbowska, Agnieszka .

CLINICAL THERAPEUTICS, 2009, 31 :2349-2370

[45] The evolving landscape in the therapy of acute myeloid leukemia [J].

Peloquin, Grace L. ;

Chen, Yi-Bin ;

Fathi, Amir T. .

PROTEIN & CELL, 2013, 4 (10) :735-746

[46] Molecular Genetic Markers in Acute Myeloid Leukemia [J].

Yohe, Sophia .

JOURNAL OF CLINICAL MEDICINE, 2015, 4 (03) :460-478

[47] Acute myeloid leukemia management and research in 2025 [J].

Kantarjian, Hagop M. ;

Dinardo, Courtney D. ;

Kadia, Tapan M. ;

Daver, Naval G. ;

Altman, Jessica K. ;

Stein, Eytan M. ;

Jabbour, Elias ;

Schiffer, Charles A. ;

Lang, Amy ;

Ravandi, Farhad .

CA-A CANCER JOURNAL FOR CLINICIANS, 2025, 75 (01) :46-67

[48] Advances in acute myeloid leukemia [J].

Newell, Laura F. ;

Cook, Rachel J. .

BMJ-BRITISH MEDICAL JOURNAL, 2021, 375 :n2026

[49] Pharmacogenomics in acute myeloid leukemia [J].

Roumier, Christophe ;

Cheok, Meyling H. .

PHARMACOGENOMICS, 2009, 10 (11) :1839-1851

[50] Immunotherapy in Acute Myeloid Leukemia [J].

Grosso, Dolores A. ;

Hess, Rosemary C. ;

Weiss, Mark A. .

CANCER, 2015, 121 (16) :2689-2704

← 1 2 3 4 5 →